GLP-1s can help with weight loss, but research shows that most Americans stop taking them within a year
Semaglutide injections work by mimicking glucagon-like peptide-1, a hormone that regulates appetite and blood sugar
Yung-Chieh Huang In a retrospective cohort study, Fu, Yung-Chieh Huang, MD, and colleagues evaluated patients aged 12 to 18 years with asthma and overweight/obesity via Jan
Christian works with individuals suffering with obesity
Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for weight management in adults with obesity or overweight with weight-related comorbidities, as an adjunct to reduced-calorie diet and increased physical activity
What the Brand Says About How These Medications May Work The brand's materials describe semaglutide as a medication that "may work through the GLP-1 pathway" and tirzepatide as one that "may work through both GIP and GLP-1 pathways." Per the official website, GLP-1-based treatment "may be considered as part of a broader provider-guided care plan for weight care," and the brand frames weight care generally as involving "a range of factors, including appetite signaling, metabolism, and overall health history" - not a single mechanism or a guaranteed outcome